Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy

Journal of Immunology

Volumn 164, Issue 6, 2000, Pages 3112-3122

  Narvaiza, Iñigo ^a   Mazzolini, Guillermo ^a   Barajas, Miguel ^a   Duarte, Marina ^a   Zaratiegui, Mikel ^a   Qian, Cheng ^a,b   Melero, Ignacio ^a,b   Prieto, Jesús ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOTAXIS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN ADENOVIRUS 2; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOBLOTTING; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TH2 CELL; TUMOR REGRESSION; TUMOR VASCULARIZATION;

EID: 0034653833     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.6.3112     Document Type: Article

References (52)

1. Luster, A. D., and J. V. Ravetch. 1987. Genomic characterization of a γ-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive site. Mol. Cell Biol. 7:3723.
2. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol. 61:246.
3. Ohmori, Y., and T. A. Hamilton. 1990. A macrophage LPS-inducible early gene encodes the murine homologue of IP-10. Biochem. Biophys. Res. Commun. 168: 1261.
4. Vanguri, P., and J. M. Farber. 1990. Identification of CRG-2: an interferon-inducible mRNA predicted to encode a murine monokine. J. Biol. Chem. 265: 15049.
5. Loetscher, M., P. Loetscher, N. Brass, E. Meese, and B. Moser. 1998. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur. J. Immunol. 28:3696.
6. Weng, Y., S. J. Siciliano, K. E. Waldburger, A. Sirotina-Meisher, M. J. Staruch, B. L. Daugherty, S. L. Gould, M. S. Springer, and J. A. DeMartino. 1998. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem. 273:18288.
7. Tamaru, M., Y. Tominaga, K. Yatsunami, and S. Narumi. 1998. Cloning of the murine interferon-inducible protein 10 (IP-10) receptor and its specific expression in lymphoid organs. Biochem. Biophys. Res. Commun. 251:41.
8. Taub, D. D., A. R. Lloyd, K. Conlon, J. M. Wang, J. R. Ortaldo, A. Harada, K. Matsushima, D. J. Kelvin, and J. J. Oppenheim. 1993. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177:1809.
9. 2+ mobilization, and enzyme release. J. Immunol. 156:322.
10. Taub, D. D., T. J. Sayers, C. R. Carter, and J. R. Ortaldo. 1995. α and β chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155:3877.
11. Luster, A. D., and P. Leder. 1993. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1057.
12. Sgadari, C., A. L. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheikh, G. Gupta, et al. 1996. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93:13791.
13. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155.
14. Angiolillo, A. L., C. Sgadari, and G. Tosato. 1996. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann. NY Acad. Sci. 795:158.
15. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182:219.
16. Kanegane, C., C. Sgadari, H. Kanegane, J. Teruya-Feldstein, L. Yao, G. Gupta, J. M. Farber, F. Liao, L. Liu, and G. Tosato. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukocyte Biol. 64:384.
17. Dilloo, D., K. Bacon, W. Holden, W. Zhong, S. Burdach, A. Zlotnik, and M. Brenner. 1996. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 2:1090.
18. Maric, M., L. Chen, B. Sherry, and Y. Liu. 1997. A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1α. J. Immunol. 159:360.
19. Ramarathinam, L., M. Castle, Y. Wu, and Y. Liu. 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
20. Emtage, P. C., Y. Wan, M. Hitt, F. L. Graham, W. J. Muller, A. Zlotnik, and J. Gauldie. 1999. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum. Gene Ther. 10:697.
21. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
22. Johnson, L. L., and P. C. Sayles. 1997. Interleukin-12, dendritic cells, and the initiation of host-protective mechanisms against Toxoplasma gondii. J. Exp. Med. 186:1799.
23. Ma, X., M. Aste-Amezaga, G. Gri, F. Gerosa, and G. Trinchieri. 1997. Immunomodulatory functions and molecular regulation of IL-12. Chem. Immunol. 68:1.
24. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581.
25. Car, B. D., V. M. Eng, J. M. Lipman, and T. D. Anderson. 1999. The toxicology of interleukin-12: a review. Toxicol. Pathol. 27:58.
26. Lotze, M. T., L. Zitvogel, R. Campbell, P. D. Robbins, E. Elder, C. Haluszczak, D. Martin, T. L. Whiteside, W. J. Storkus, and H. Tahara. 1996. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann. NY Acad. Sci. 795:440.
27. Mazzolini, G., C. Qian, X. Xie, Y. Sun, J. J. Lasarte, M. Drozdzik, and J. Prieto. 1999. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther. 6:514. 2000.
28. Douin-Echinard, V., P. D. Robbins, M. T. Lotze, G. Favre, and B. Couderc. 1998. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70. Adv. Exp. Med. Biol. 451:353.
29. Caruso, M., K. Pham-Nguyen, Y. L. Kwong, B. Xu, K. I. Kosai, M. Finegold, S. L. Woo, and S. H. Chen. 1996. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. USA 93:11302.
30. Gambotto, A., T. Tuting, D. L. McVey, I. Kovesdi, H. Tahara, M. T. Lotze, and P. D. Robbins. 1999. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther. 6:45.
31. Hardy, S., M. Kitamura, T. Harris-Stansil, Y. Dai, and M. L. Phipps. 1997. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71: 1842.
32. Brattain, M. G., J. Strobel-Stevens, D. Fine, M. Webb, and A. M. Sarrif. 1980. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40:2142.
33. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877.
34. Qian, C., M. Idoate, R. Bilbao, B. Sangro, O. Bruna, J. Vazquez, and J. Prieto. 1997. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum. Gene Ther. 8:349.
35. Qian, C., R. Bilbao, O. Bruna, and J. Prieto. 1995. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 22:118.
36. Schagger, H., and G. von Jagow. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368.
37. Vicente-Manzanares, M., M. C. Montoya, M. Mellado, J. M. Frade, M. A. del Pozo, M. Nieto, M. O. de Landazuri, A. C. Martinez, and F. Sanchez-Madrid. 1998. The chemokine SDF-1α triggers a chemotactic response and induces cell polarization in human B lymphocytes. Eur. J. Immunol. 28:2197.
38. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immuno-dominant major histocompatibility complex class 1-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93:9730.
39. Van den Eynde, B., B. Lethe, A. Van Pel, E. De Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
40. Borras-Cuesta, F., A. Petit-Camurdan, and Y. Fedon. 1987. Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells. Eur. J. Immunol. 17:1213.
41. Melero, I., M. C. Singhal, P. McGowan, H. S. Haugen, J. Blake, K. E. Hellstrom, G. Yang, C. H. Clegg, and L. Chen. 1997. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:3998.
42. Mazzolini, G, C. Qian, I. Narvaiza, M. Barajas, F. Borrás-Cuesta, X. Xie, M. Duarte, I. Melero, and J. Prieto. 2000. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum. Gene Ther. 11:113.
43. Gambotto, A., T. Tuting, D. L. McVey, I. Kovesdi, H. Tahara, M. T. Lotze, and P. D. Robbins. 1999. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther. 6:45.
44. Dranoff, G., and R. C. Mulligan. 1995. Gene transfer as cancer therapy. Adv. Immunol. 58:417.
45. Paillard, F. 1999. Cytokine and chemokine: a stimulating couple. Hum. Gene Ther. 10:695.
46. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
47. Lanzavecchia, A. 1998. Immunology: licence to kill. Nature 393:413.
48. Yao, L., C. Sgadari, K. Furuke, E. T. Bloom, J. Teruya-Feldstein, and G. Tosato. 1999. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93:1612.
49. Kodama, T., K. Takeda, O. Shimozato, Y. Hayakawa, M. Atsuta, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura. 1999. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29:1390.
50. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623.
51. Melero, I., J. V. Johnston, W. W. Shufford, R. S. Mittler, and L. Chen. 1998. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunoi. 190:167.
52. Melcher, A., S. Todryk, N. Hardwick, M. Ford, M. Jacobson, and R. G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:581.